Company Cyclacel Pharmaceuticals Inc Nasdaq

Equities

US23254L1089

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jun. 26	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jun. 26	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

USD in Million	2022	Weight	2023	Weight	Delta
Cancer Medicines 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Spiro Rombotis CEO	Chief Executive Officer	65	97-07-31
Paul McBarron DFI	Director of Finance/CFO	63	01-12-31
Brian Schwartz CTO	Chief Tech/Sci/R&D Officer	52	20-12-16

Members of the board	Title	Age	Since
Christopher Henney BRD	Director/Board Member	83	06-02-28
Brian Schwartz CTO	Chief Tech/Sci/R&D Officer	52	20-12-16
Spiro Rombotis CEO	Chief Executive Officer	65	97-07-31
Paul McBarron DFI	Director of Finance/CFO	63	01-12-31
Robert Spiegel BRD	Director/Board Member	73	18-09-11
Samuel Barker CHM	Chairman	81	14-09-10
Kenneth Ferguson BRD	Director/Board Member	68	22-06-13
Karin Walker BRD	Director/Board Member	60	20-11-08

	Vote	Quantity	Free-Float	Total Float
Stock A	0	264	0	75.37 %
Stock B	1	1,463,259	1,355,555 ( 92.64 %)
Stock C	0	335,273	0

Name	Equities	%	Valuation
Spiro Rombotis 2.050 %	30,000	2.050 %	48 600 $
Renaissance Technologies LLC 1.424 %	20,838	1.424 %	33 758 $
Brian Schwartz 1.142 %	16,707	1.142 %	27 065 $
Paul McBarron 1.110 %	16,241	1.110 %	26 310 $
Point72 Asset Management LP 1.048 %	15,333	1.048 %	24 839 $
Acadian Asset Management LLC 0.9762 %	14,285	0.9762 %	23 142 $
The Lind Partners LLC 0.3800 %	5,561	0.3800 %	9 009 $
UBS Securities LLC 0.3304 %	4,835	0.3304 %	7 833 $
Karin Walker 0.2875 %	4,207	0.2875 %	6 815 $
Tower Research Capital LLC 0.2862 %	4,188	0.2862 %	6 785 $

Name	Equities	%	Valuation
Acorn Capital Advisors LLC -	119,000	-	192 780 $

Name	Equities	%	Valuation
Spiro Rombotis 0.4772 %	1,600	0.4772 %	15 120 $
Sound Income Strategies LLC 0.0280 %	94	0.0280 %	888 $

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive Suite 1500

07922, Berkeley Heights

+908 517 7330

http://www.cyclacel.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs